3 Pharma Stocks in Focus: Ajanta, Zydus, Emcure Updates Revealed

• Ajanta Pharma partnered with Biocon for exclusive marketing of Semaglutide (GLP-1 receptor agonist) in 23 countries, with launch planned for late 2026/early 2027.
• Zydus Lifesciences collaborated with Bioeq AG for US commercialization of NUFYMCO, an interchangeable biosimilar of Lucentis, approved by US FDA on Dec 18.
• Emcure Pharma's Gujarat unit received a 'No Action Indicated' (NAI) Establishment Inspection Report (EIR) from the US FDA after an inspection with no observations.
• Ajanta Pharma shares closed down 1%, while Zydus Lifesciences and Emcure Pharma shares rose 1.2% and 3.4% respectively in the previous session.

Why It Matters: Key updates on licensing deals and FDA reports put Ajanta, Zydus, and Emcure Pharma in focus.